Biocentis

📍 Milan, Italy🗓 Founded 2022👥 19 employees💰 Last funded Feb 2024
Biocentis is an Imperial College London spin-out on a mission to develop eco-friendly genetic solutions to effectively and safely control the dangerous insect species that spread disease to humans, reduce biodiversity, or threaten food security. We leverage CRISPR to develop self-limiting gene drive technologies that are biological, environmentally friendly, and can be tailored to obtain levels of control that are suitable for a broad range of applications. Building on a unique proprietary technological platform, invented by our founders at Imperial College London and applicable to all insect species, Biocentis aims to re-imagine the future of biocontrol. We want to empower communities around the world to tackle the most dangerous insect vectors of disease, to preserve biodiversity and to protect agricultural crops from harmful insect pests. Our vision is a more sustainable world, capable of feeding a growing population and free of vector-borne disease. With offices in Milan and London and a presence in the US, we employ a diverse and accomplished team with unparalleled experience in the scientific and technological fields and an outstanding track record in company building and management. We are also growing very fast, and we encourage you to reach out if you want to be part of our journey.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2022
Founded
Investor geography2 countries
Luxembourg
1
Italy
1
Frequently asked questions
Who invested in Biocentis?
Biocentis has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Biocentis last raise funding?
The most recent investment in Biocentis recorded on gritt.io was in February 2024.
When was Biocentis founded?
Biocentis was founded in 2022.
What industry is Biocentis in?
Biocentis operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Biocentis based?
Biocentis is headquartered in Milan, Italy.